Tissue Regenix (TRX): Maiden pre-tax profit

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated seven consecutive reporting periods of strong growth, with TRX becoming profitable in 1H’24. TRX is about to invest

Hybridan Small Cap Feast - 10 September 2024

* A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: Hermes Pacific Investments (HPAC.L) has delisted from AIM What’s baking in the oven? Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”. Hybridan Chefs research@hybr

Morning Note – 10 September 2024

Tissue Regenix - Interims: Delivering continued progress

Tissue Regenix has reported its results for the six months to June 2024. Revenues were $16.4m, up 16% versus H1/23, delivering the seventh consecutive period of double-digit revenue growth. Group revenues were supported by both key divisions, BioRInse and dCELL (+12% and +34%, respectively). Gross margin improved 340bps versus H1/23 on improved efficiency and favourable product mix. Tissue Regenix remained profitable at the adjusted EBITDA level, generating $1.1m of profit, more than double the

Hybridan Small Cap Feast - 16 July 2024

16th July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to co

Morning Note – 16 July 2024

Tissue Regenix - Positive trading update

Tissue Regenix has maintained its strong performance, expecting to deliver 16% revenue growth over the first half period to June 2024, generating revenues of c$16.4m. This represents the seventh consecutive reporting period of revenue growth, with Tissue Regenix delivering an average of c20% revenue growth per period across these seven half-year intervals. Furthermore, the company expects its adjusted EBITDA to grow in H1/24 versus the H1/23 profit of $0.35m. We believe Tissue Regenix’s 4S Strat

Hardman & Co Insight: Survival of the UK life sciences sector

For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises. However, the small- and mid-cap life sciences sector has alway

Hardman & Co Research: Tissue Regenix (TRX) - Six consecutive periods of >20% growth

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. Further growth in 202

Morning Note – 19 March 2024

Tissue Regenix - Record revenues and profitability

Tissue Regenix has reported on strong performance through 2023, noting record revenues driven by product adoption and expanded distribution, positive adjusted EBITDA for the first time and an increased cash position versus H1/23. FY23 revenues grew 20% to $29.5m supported by 25% growth from BioRinse products and 17% growth from dCELL products. Significantly, Tissue Regenix reported its first adjusted EBITDA profit for the year, +$0.9m, supported by revenue growth and cost management. We expect t

Morning Note – 6 February 2024

Tissue Regenix - 4S Strategy in Europe

Tissue Regenix has announced positive developments to expand its operations in Europe, following the approval of its Irish logistics hub, received in October 2023. The company has made its first shipment of allograft products from the Irish hub, marking a key milestone for the European market. Additionally, Tissue Regenix has signed new distributors covering Ireland (including Northern Ireland) and Turkey. These agreements follow the signing of a Spanish distributor in October 2023. We see both

Hybridan Small Cap Feast - 25 Jan 24

25th January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje